SCHEMBL9364940

SCHEMBL9364940

COc1cccc2c1CCC(=O)N2CCCN1CCN(c2ccccc2)CC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.81
DRD2 P14416 4/20 0.65
DRD4 P21917 4/20 0.65
DRD3 P35462 4/20 0.65
MEN1 O00255 1/20 0.65
CYP1A2 P05177 1/20 0.65
HTR1A P08908 1/20 0.65
CYP2C9 P11712 1/20 0.65
CYP2C19 P33261 1/20 0.65
HTR7 P34969 1/20 0.65
KMT2A Q03164 1/20 0.65
ADRB2 P07550 1/20 0.65
CHRM2 P08172 1/20 0.65
CHRM4 P08173 1/20 0.65
ADRB1 P08588 1/20 0.65
CHRM5 P08912 1/20 0.65
CHRM1 P11229 1/20 0.65
CHRM3 P20309 1/20 0.65
ADRA1D P25100 1/20 0.65
ADRA1A P35348 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9085153 0.99 SIGMAR1 (0.80) SIGMAR1DRD2DRD4DRD3MEN1
SCHEMBL9364910 0.91 SIGMAR1 (0.84) SIGMAR1DRD2DRD4DRD3MEN1
SCHEMBL29405772 0.90 SIGMAR1 (1.00) SIGMAR1DRD2DRD4DRD3
SCHEMBL30279503 0.90 SIGMAR1 (1.00) SIGMAR1DRD2DRD4DRD3
SCHEMBL14038154 0.90 SIGMAR1 (0.82) SIGMAR1DRD2DRD4DRD3MEN1
SCHEMBL9082184 0.90 SIGMAR1 (0.82) SIGMAR1DRD2DRD4DRD3MEN1
SCHEMBL5022801 0.90 SIGMAR1 (1.00) SIGMAR1DRD2DRD4DRD3
SCHEMBL8845371 0.89 SIGMAR1 (0.81) SIGMAR1DRD2DRD4DRD3MEN1
Hydrochloric Acid SCHEMBL8844768 0.89 SIGMAR1 (0.98) SIGMAR1DRD2DRD4DRD3
SCHEMBL9364298 0.88 SIGMAR1 (0.77) SIGMAR1DRD2DRD4DRD3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0512525-B1 Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist OTSUKA PHARMA CO LTD (JP) 1994-11-30 EP claimed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR6, GAP43, HTR5A SIGMAR1 201/4885DRD2 242/4885DRD4 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.